Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women

European Journal of Clinical Pharmacology

Volumn 59, Issue 5-6, 2003, Pages 471-476

  Huang, Ping ^b   Zhu, Bing ^a   Wang, Lian Sheng ^a   Ouyang, Dong Sheng ^a   Huang, Song Lin ^a   Chen, Xiao Ping ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUNAN CANCER HOSPITAL   (China)

Author keywords

Breast cancer; CYP3A; Midazolam

Indexed keywords

1 HYDROXYMIDAZOLAM; 16ALPHA HYDROXYESTRONE; CYTOCHROME P450 3A; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; MIDAZOLAM; MIDAZOLAM MALEATE; PROGESTERONE RECEPTOR; STEROID HORMONE; UNCLASSIFIED DRUG;

ADULT; AEROBIC METABOLISM; AGED; ARTICLE; BLOOD SAMPLING; BREAST CARCINOMA; BREAST CELL; BREAST EPITHELIUM; CANCER CELL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHINESE; CHROMATOGRAPHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; EVALUATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROXYLATION; LYMPH NODE METASTASIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; VOLUNTEER;

ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CHINA; CYTOCHROME P-450 CYP3A; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDAZOLAM; OXIDOREDUCTASES, N-DEMETHYLATING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 0141817780     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0649-4     Document Type: Article

References (32)

1. Lacey JV Jr, Devesa SS, Brinton LA (2002) Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen 39:82-88
2. Key TJ (1999) Serum oestradiol and breast cancer risk. Endocr Relat Cancer 6:175-180
3. Colditz GA (1998) Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 90:814-823
4. Key TJ, Verkasalo PK, Banks E (2001) Epidemiology of breast cancer. Lancet Oncol 2:133-140
5. Key TJ, Pike MC (1988) The role of oestrogens and progestrogens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 24:29-43
6. Yager JD (2000) Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 27:67-73
7. Zhu BT, Conney AH (1998) Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19:1-27
8. Liehr JG (1997) Dual role of oestrogens as hormones and procarcinogens: tumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev 6:3-10
9. Cavalieri EL, Stack DE, Devanesan PD, et al (1997) Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci U S A 94:10937-10942
10. Huang ZQ, Guengerich FP, Kaminsky LS (1998) 16α-hydroxylation of estrone by human cytochrome P450 3A4/5. Carcinogenesis 19:867-872
11. Shou M, Korzekwa KR, Brooks EN, Krausz KW, Gonzalez FJ, Gelboin HV (1997) Role of human hepatic cytochrome CYP1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis 18:207-214
12. Huang ZQ, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS (1996) Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 24:899-905
13. Galant C, Gala JL, Van Den Berge V, Berliere M, Haumont E, Horsmans Y (2001) Immunolocalisation of cytochrome P-450 3A enzymes in human breast carcinoma: relationship with tumour differentiation and steroid receptors. Pharmacol Toxicol 88:142-146
14. Zheng W, Jin F, Dunning LA, et al (2001) Epidemiological study of urinary 6β-hydroxycortisol to cortisol ratios and breast cancer risk. Cancer Epidemiol Biomarkers Prey 10:237-242
15. Horita K, Yamaguchi A, Hirose K, et al (2001) Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer. Eur J Histochem 45:73-84
16. Paulussen A, Lavrijsen K, Bohets H, et al (2000) Two linked mutatuins in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 10:415-424
17. Streetman DS, Bertino JS, Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187-216
18. Zhu B, Ou-Yang DS, Cheng ZN, Huang SL, Zhou HH (2001) Single plasma sampling to predict oral clearance of the CYP3A probe midazolam. Acta Pharmacologica Sinica 22:634-638
19. Watkins PB (1995) Cyclosporine and liver transplantation: will the midazolam test make blood level monitoring obsolete? Hepatology 22:994-995
20. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN (1999) Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 37:485-505
21. Schmucker DL, Woodhouse KW, Wang RK, et al (1990) Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 48:365-374
22. Kinirons MT, O'Shea D, Downing TE, et al (1993) Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 54:621-629
23. Hunt CM, Westerkam WR, Stave GM (1992) Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44:275-283
24. Hunt CM, Watkins PB, Saenger P, et al (1992) Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 51:18-23
25. Hashimoto H, Toide K, Kitamura R, et al (1993) Gene structure of CYP3A4, and adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 218:585-595
26. Abrams JS (2001) Adjuvant therapy for breast cancer - results from the USA consensus conference. Breast Cancer 8:298-304
27. Shimada T, Guengerich FP (1989) Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc Natl Acad Sci U S A 86:462-465
28. Lown KS, Thummel KE, Benedict PE, et al (1995) The erythromycin breast test predicts the clearance of midazolam. Clin Pharmacol Ther 57:16-24
29. Hsieh KP, Lin YY, Cheng CL, et al (2001) Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 29:268-273
30. Gorski JC, Hall SD, Jones DR, Vanden-branden M, Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653
31. Sheweita SA (2000) Drug-metabolizing enzymes: mechanisms and functions. Curr Drug Metab 1:107-132
32. Miyoshi Y, Ando A, Takamura Y, Taguchi T, Tamaki Y, Noguchi S (2002) Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer 97:129-132